2-hydrazonoimidazolidine hydroiodide | 39889-17-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 英文名称: 2-hydrazonoimidazolidine hydroiodide
• 英文别名: imidazolidin-2-one-hydrazone; hydriodide；Imidazolidin-2-on-hydrazon; Hydrojodid；2-hydrazino-4,5-dihydro-1H-imidazole hydroiodide；4,5-dihydro-1H-imidazol-2-ylhydrazine;hydroiodide
• CAS: 39889-17-3
• 化学式: C₃H₈N₄*HI
• 分子量: 228.036
• InChiKey: SCWOANXBMXJDAP-UHFFFAOYSA-N

物化性质

• 熔点：
  139-140 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.97
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  62.4
• 氢给体数：
  4
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-hydrazonoimidazolidine hydroiodide 在 盐酸 、 硝酸 、 silver nitrate 、 sodium nitrite 、 potassium carbonate 作用下， 以 水 为溶剂， 反应 1.17h， 以75%的产率得到5,6-二氢-4H-咪唑[1,2-d]四唑
  参考文献：
  名称：

  N-亚硝基和N-氨基四唑

  摘要：

  Ñ -Nitroso-（图5a，Ç）和Ñ -nitraminotetrazoles（6A - C ^）从相应的aminotetrazoles（合成3A - C ^）或者通过用乙酸酐/ HNO的直接硝化3或由相应的硝酸盐的脱水（4A - c）用浓硫酸。所述的转化Ñ -nitrosoaminotetrazoles（图5a，Ç）与过氧三氟乙酸（CF 3 CO 3 1H），得到高产率的相应的硝胺（6A（82％），6c（80％））。所述Ñ -nitroso-（图5a，Ç）和Ñ -nitraminotetrazoles（6A - C ^）已经被完全表征通过振动（IR，拉曼）和多核NMR谱（14 N / 15 N，1 H，13 C），质谱法以及元素分析。给出了对15 N化学位移和1 H- 15 N耦合常数的详细讨论。固态的分子结构通过单晶X射线衍射确定（3a，c，5a，c ; 6a - c）和分子结构的

  DOI：

  10.1021/jo0513820
• 作为产物：
  描述：

  亚乙基硫脲 在 碘甲烷 、 一水合肼 作用下， 以 乙醇 为溶剂， 反应 9.67h， 以67.42%的产率得到2-hydrazonoimidazolidine hydroiodide
  参考文献：
  名称：

  BBI608衍生物及其制备与用途

  摘要：

  本发明属于医药技术领域，涉及一类BBI608衍生物及其在抗肿瘤药物中的应用。所述衍生物及其药学上可接受的盐的结构如下：其中X、R1、R2、R3如权利要求书和说明书所述。本发明所述的衍生物及其药学上可接受的盐可用于制备抗肿瘤的药物，尤其是制备治疗胃癌(包括胃食管连接癌)和胰腺癌的药物。HepG2细胞活性研究中发现大部分化合物的细胞抑制活性明显优于抗癌药物BBI608。

  公开号：

  CN107973788B

文献信息

• 2-(Pyrrol-1-yl)amino-4,5-dihydro-1H-imidazole derivatives
  申请人：Gruppo Lepetit S.p.A.

  公开号：US03979408A1

  公开（公告）日：1976-09-07

  2-(Pyrrol-1-yl)amino-4,5-dihydro-1H-imidazole derivatives of the following general formula I ##SPC1## wherein R, R.sub.1, R.sub.2 and R.sub.3 may be the same or different and are independently selected from the class consisting of hydrogen, lower alkyl, carbo-lower alkoxy, phenyl, substituted phenyl, R.sub.4 represents hydrogen or lower alkyl, n is an integer and may be 2 or 3. The corresponding pharmaceutically acceptable acid addition salts of the substances of formula I above are considered as a part of the invention. The invention compounds display very interesting anthypertensive properties.

  通用公式I的2-(吡咯-1-基)氨基-4,5-二氢-1H-咪唑衍生物如下：其中R、R.sub.1、R.sub.2和R.sub.3可以相同也可以不同，并且独立地选自氢、较低烷基、羰基-较低烷氧基、苯基、取代苯基，R.sub.4代表氢或较低烷基，n是一个整数，可以是2或3。上述公式I物质的相应药用可接受的酸盐被视为本发明的一部分。该发明化合物具有非常有趣的降压作用。
• Process for preparing 2-hydrazino-1,3-diazacycloalk-2-ene hydrohalides
  申请人：American Cyanamid Company

  公开号：US04574155A1

  公开（公告）日：1986-03-04

  This invention provides a process for preparing a 2-hydrazino-1,3-diazacycloalk-2-ene hydrohalide. The process comprises reacting a one molar proportion of either tautomeric isomer of a 2-nitroamino-1,3-diazacycloalk-2-ene represented by the following formulas: ##STR1## wherein R.sup.1 is hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 hydroxyalkyl, C.sub.1 -C.sub.6 alkoxyalkyl, phenyl, substituted phenyl, benzyl, or substituted benzyl, R.sup.2 and R.sup.3 are independently hydrogen, C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, C.sub.1 -C.sub.6 alkoxyalkyl, hydroxyl, aryl, substituted aryl, aralkyl and substituted aralkyl, and n is an integer from 0 to 3 with about an equimolar proportion of an ammonium halide or hydrazonium halide, and about a 1 to 2 molar proportion of hydrazine hydrate in a composition selected from a C.sub.1 to C.sub.4 aliphatic alcohol, water or a mixture thereof, at a temperature from about ambient to the reflux, and isolating the end product as a monohydrohalide. This invention also provides a process for preparing a 2-hydrazino-1,3-diazacycloalk-2-ene dihydrohalide. The process comprises reacting a compound of the formula: ##STR2## wherein R.sup.1 is hydrogen, C.sub.1 to C.sub.6 alkyl, or C.sub.1 to C.sub.6 hydroxyalkyl, R.sup.2 and R.sup.3 are independently hydrogen or C.sub.1 to C.sub.6 alkyl, n is 0 to 3 and X is a halide ion, with hydrogen halide wherein the halide ion is the same as defined above in a C.sub.1 to C.sub.4 alkyl alcohol at about 0.degree. to 30.degree. C.; and recovering the corresponding 2-hydrazino-1,3-diazacycloalk-2-ene dihydrohalide.

  这项发明提供了一种制备2-叠氮基-1,3-二氮杂环戊-2-烯氢卤化物的过程。该过程包括将由以下结构式表示的2-硝基氨基-1,3-二氮杂环戊-2-烯的两种互变异构体之一的1摩尔比例与约相等摩尔比例的铵盐卤化物或叠氮盐卤化物以及约1到2摩尔比例的叠氮水合物在选择自C1至C4脂肪醇、水或二者混合物的组合物中，以约室温至沸点的温度反应，并将终产物作为单氢卤化物进行分离。该发明还提供了一种制备2-叠氮基-1,3-二氮杂环戊-2-烯二氢卤化物的过程。该过程包括将具有以下结构式的化合物：其中R1为氢、C1到C6烷基或C1到C6羟基烷基，R2和R3独立地为氢或C1到C6烷基，n为0到3，X为卤化物离子，与卤化氢在约0°C至30°C的C1到C4烷基醇中反应；并回收相应的2-叠氮基-1,3-二氮杂环戊-2-烯二氢卤化物。
• Trani; Bellasio, Farmaco, Edizione Scientifica, 1983, vol. 38, # 12, p. 940 - 949
  作者：Trani、Bellasio

  DOI：——

  日期：——
• Design, synthesis and activity of BBI608 derivatives targeting on stem cells
  作者：Qifan Zhou、Chen Peng、Fangyu Du、Linbo Zhou、Yajie Shi、Yang Du、Dongdong Liu、Wenjiao Sun、Meixia Zhang、Guoliang Chen

  DOI：10.1016/j.ejmech.2018.03.054

  日期：2018.5

  STAT3 plays a vital role in maintaining the self-renewal of tumor stem cells. BBI608, a small molecule identified by its ability to inhibit gene transcription driven by STAT3 and cancer stemness properties, can inhibit stemness gene expression and kill stemness-high cancer cells isolated from a variety of cancer types. In order to improve the pharmacokinetic properties of BBI608 and the antitumor activity, a series of BBI608 derivatives were designed and synthesized here. Most of these compounds were more potent than BBI608 on HepG2 cells, compound LD-8 had the most potent inhibitory activity among them and was 5.4-fold more potent than BBI608 (IC50 = 11.2 mu M), but had considerable activity on normal liver cells L-02. Compounds LD-17 (IC50 = 3.5 mu M) and LD-19 (10(50) = 2.9 mu M) were found to possess significant inhibitory activities and good selectivity. The results showed that compound LD-19 was worthy to investigate further as a lead compound according to its potent inhibitory activity, ideal ClogP value and better water solubility. (C) 2018 Elsevier Masson SAS. All rights reserved.
• Sidzhakova; Panajotova; Mardirossjan, Pharmazie, 1993, vol. 48, # 6, p. 417 - 419
  作者：Sidzhakova、Panajotova、Mardirossjan、Tabakova、Maneva、Marinova、Golovinsky

  DOI：——

  日期：——